Format

Send to

Choose Destination
Curr Top Microbiol Immunol. 2011;352:27-42. doi: 10.1007/82_2011_129.

Clinical experience with recombinant molecules for allergy vaccination.

Author information

1
Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, 21465 Reinbek, Germany. oliver.cromwell@allergopharma.de

Abstract

Numerous allergens have been cloned and produced by the use of recombinant DNA technology. In several cases recombinant variants with reduced IgE-reactivity have also been developed as candidates for allergen specific immunotherapy. Only very few of these proteins have as yet been tested in the clinic, and the major focus has been on birch and grass pollen, two of the most common causes of IgE-mediated allergic disease. This article serves to justify the rational for using recombinant products and reviews the progress that has been made to date with their clinical assessment.

PMID:
21562972
DOI:
10.1007/82_2011_129
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center